Bio-Techne TECH Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Bio-Techne in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Bio-Techne’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bio-Techne's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bio-Techne's cash & equivalents?
- Bio-Techne (TECH) reported cash & equivalents of $209.82M in Q1 2026.
- How has Bio-Techne's cash & equivalents changed year-over-year?
- Bio-Techne's cash & equivalents increased by 49.2% year-over-year, from $140.67M to $209.82M.
- What is the long-term trend for Bio-Techne's cash & equivalents?
- Over 4 years (2021 to 2025), Bio-Techne's cash & equivalents has grown at a -5.0% compound annual growth rate (CAGR), from $199.09M to $162.19M.
- What does cash & equivalents mean?
- The total amount of cash and highly liquid assets the company can access immediately.
- How do you interpret cash & equivalents?
- An increase suggests strong liquidity and potential for investment, while a decrease may indicate heavy capital expenditure or cash burn.
- How does cash & equivalents compare across companies?
- Peers in the life sciences sector typically maintain cash balances proportional to their R&D spending and M&A strategy.